

Related Change Request (CR) #: 3153

Medlearn Matters Number: MM3153

Related CR Release Date: March 26, 2004

Related CR Transmittal #:131

Effective Date: January 1, 2004

Implementation Date: March 26, 2004

MMA - New Payment Allowance Percentages for DMERC Drugs

Provider Types Affected

Suppliers and other providers who bill for certain drugs and biologicals not paid on a cost or prospective payment basis.

Provider Action Needed

Affected providers and suppliers should note that this instruction adds a payment limit percentage for the drug Capecitabine (Xeloda).

Background

Effective January 1, 2004, the payment limit allowance for J8520 (Capecitabine, 150 mg) and J8521 (Capecitabine, 500 mg) will be 90 percent of the April 1, 2003 Average Wholesale Price (AWP). While this change is effective for these codes as of January 1, 2004, Medicare does not plan to search their files to make any adjustment to claims already processed, unless the provider brings such claims to the attention of their DMERC or fiscal intermediary (FI).

Implementation

The implementation date for this instruction is March 26, 2004.

Additional Information

The official instruction issued to your carrier regarding this change may be found by going to:

http://www.cms.hhs.gov/manuals/pm_trans/R131CP.pdf

If you have any questions, please contact your DMERC/FI at their toll-free number, which may be found at:

<http://www.cms.hhs.gov/medlearn/tollnums.asp>

Disclaimer

Medlearn Matters articles are prepared as a service to the public and are not intended to grant rights or impose obligations. Medlearn Matters articles may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.